Monday, April 20, 2026 – Monday, April 20 - Ozempic’s weight loss benefits might come at the cost of muscle strength, even if muscle size remains relatively stable. This raises significant concerns for older adults, who are already at risk for muscle loss and reduced mobility. Researchers stress the urgent need for human clinical trials to understand these effects fully.
Monday, April 20, 2026 – Monday, April 20 - Scientists are racing to improve weight loss treatments beyond drugs like Ozempic and Wegovy, which are effective but plagued by nausea, bone loss, and weight regain. Tufts University chemists have created a new multi-target compound that goes beyond the usual GLP-1, GIP, and glucagon approaches by adding a fourth hormone, PYY. This “quadruple-action” design aims to deliver weight loss results on par with bariatric surgery—up to 30%—without invasive procedures, and could change the future of obesity treatment.
Monday, April 20, 2026 – Monday, April 20 - Some people taking Ozempic, Wegovy, or Mounjaro notice that food suddenly tastes sweeter or saltier, and this subtle shift in flavor perception appears tied to reduced appetite and stronger feelings of fullness. In a study of more than 400 patients, roughly one in five experienced heightened taste sensitivity, and many reported being less hungry and more easily satisfied.
Monday, April 20, 2026 – Monday, April 20 - Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems tied not just to slimming down but to deeper biological effects on inflammation, blood pressure, and vessel health. Researchers say this could expand who qualifies for the drug.
Monday, April 20, 2026 – Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels. With a safety profile consistent with existing treatments, experts see it as a breakthrough for patients preferring oral options.
Monday, April 20, 2026 – Scientists are uncovering how GLP-1 drugs like Ozempic and Wegovy act on brain regions that control hunger, nausea, pleasure-based eating, and thirst. These discoveries may help create treatments that keep the benefits of weight loss while reducing unwanted side effects.
Monday, April 20, 2026 – Audience: Consumer PLAINSBORO, NJ, December 5, 2025 - FDA recently seized dozens of units of counterfeit Ozempic (semaglutide) injection 1 mg distributed illegally outside of Novo Nordisk’s authorized supply chain. The US Food and Drug...
Monday, April 20, 2026 – Monday, April 20 - Deep-brain recordings showed that Mounjaro and Zepbound briefly shut down the craving circuits linked to food noise in a patient with severe obesity. Her obsessive thoughts about food disappeared as the medication quieted the nucleus accumbens, the brain’s reward hub.
Monday, April 20, 2026 – Bariatric surgery far outperformed GLP-1 weight loss drugs in a new real-world comparison of more than 50,000 patients. Two years after treatment, surgery patients lost about 58 pounds on average, while those using semaglutide or tirzepatide lost roughly 12 pounds. Even patients who stayed on GLP-1 drugs for a full year saw much smaller results than surgical patients. High dropout rates and real-world challenges appear to blunt the drugs’ effectiveness.
Monday, April 20, 2026 – Audience: Health Care Professional, Consumer January 13, 2026
FDA Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With the Use of GLP-1 RA Medications
This information is an update to the FDA Drug Safety...